Avisa Diagnostics Inc
CNSX:AVBT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Avisa Diagnostics Inc
Income from Continuing Operations
Avisa Diagnostics Inc
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Avisa Diagnostics Inc
CNSX:AVBT
|
Income from Continuing Operations
-$715.8k
|
CAGR 3-Years
-151%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Income from Continuing Operations
$7.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
1%
|
CAGR 10-Years
1%
|
|
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
Income from Continuing Operations
$313.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Revolution Medicines Inc
NASDAQ:RVMD
|
Income from Continuing Operations
-$1.1B
|
CAGR 3-Years
-66%
|
CAGR 5-Years
-60%
|
CAGR 10-Years
N/A
|
|
|
United Therapeutics Corp
NASDAQ:UTHR
|
Income from Continuing Operations
$1.3B
|
CAGR 3-Years
22%
|
CAGR 5-Years
21%
|
CAGR 10-Years
7%
|
|
|
Moderna Inc
NASDAQ:MRNA
|
Income from Continuing Operations
-$2.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
Avisa Diagnostics Inc
Glance View
Avisa Diagnostics, Inc. is a clinical stage medical device company. The company is headquartered in Santa Fe, New Mexico. The company went IPO on 2010-02-16. The firm develops the Avisa BreathTest, a drug/device biomarker technology platform that enables the detection of bacterial pathogens, detecting and monitoring bacterial load after the patient inhales or ingests its drug substrates. The firm conducts trials in cystic fibrosis, tuberculosis and community-acquired pneumonia. Its drug/device is in late-stage clinical development, which measures the lung and live organisms. The firm develops, AVISARTM instrument, which contains a touchscreen operator interface, nebulizer controller, breath sampling pneumatics and a laser spectrometer. Its Avisa BreathTest kit contains lyophilized AV-U13 drug, pre-filled syringe of sterile water, breath collection and biologic filter components and aerogen solo mesh nebulizer.
See Also
What is Avisa Diagnostics Inc's Income from Continuing Operations?
Income from Continuing Operations
-715.8k
USD
Based on the financial report for Dec 31, 2020, Avisa Diagnostics Inc's Income from Continuing Operations amounts to -715.8k USD.
What is Avisa Diagnostics Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 3Y
-151%
Over the last year, the Income from Continuing Operations growth was 83%. The average annual Income from Continuing Operations growth rates for Avisa Diagnostics Inc have been -151% over the past three years .
